In-vivo detectable antibodies directed against the oncofetal antigen/immature laminin receptor can recognize and control myeloma cells--clinical implications.
Siegel
S
S
Friedrichs
B
B
Budde
A-K
AK
Barsoum
A
A
Coggin
J
J
Tiemann
M
M
Kabelitz
D
D
Zeis
M
M
D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000378:metabolism; D016022:Case-Control Studies; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006801:Humans; D007124:Immunoenzyme Techniques; D007952:Leukemia, Plasma Cell / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D009101:Multiple Myeloma / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D010265:Paraproteinemias / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D017474:Receptors, Laminin / Q000235:genetics / Q000276:immunology*; D012269:Ribosomal Proteins / Q000235:genetics / Q000276:immunology*
D000912:Antibodies, Neoplasm; C510624:RPSA protein, human; D017474:Receptors, Laminin; D012269:Ribosomal Proteins